Antonia Manduca, Valeria Buzzelli, Alessandro Rava, Alessandro Feo, Emilia Carbone, Sara Schiavi, Barbara Peruzzi, Valentina D'Oria, Marco Pezzullo, Andrea Pasquadibisceglie, Fabio Polticelli, Vincenzo Micale, Martin Kuchar, Viviana Trezza
Cannabidiol (CBD), a non-psychotomimetic constituent of Cannabis sativa, has been recently approved for epileptic syndromes often associated with Autism spectrum disorder (ASD). However, the putative efficacy and mechanism of action of CBD in patients suffering from ASD and related comorbidities remain debated, especially because of the complex pharmacology of CBD. We used pharmacological, immunohistochemical and biochemical approaches to investigate the effects and mechanisms of action of CBD in the recently validated Fmr1-Δ exon 8 rat model of ASD, that is also a model of Fragile X Syndrome (FXS), the leading monogenic cause of autism...
April 5, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society